Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 42Rectal Neoplasms 31Colorectal Neoplasms 31Pancreatic Neoplasms 30Neoplasms 26Stomach Neoplasms 20Neoplasm Metastasis 17Colonic Neoplasms 13Unspecified Adult Solid Tumor, Protocol Specific 12Esophageal Neoplasms 12Carcinoma, Non-Small-Cell Lung 11Solid Tumor 7Biliary Tract Neoplasms 7Squamous Cell Carcinoma of Head and Neck 4Ovarian Neoplasms 4Liver Neoplasms 4Carcinoma, Hepatocellular 4Bile Duct Neoplasms 4Triple Negative Breast Neoplasms 3Prostatic Neoplasms 3Melanoma 3Head and Neck Neoplasms 3Gallbladder Neoplasms 3Carcinoma, Renal Cell 3Carcinoma, Ovarian Epithelial 3Appendiceal Neoplasms 3Anus Neoplasms 3Adenocarcinoma 3Vaginal Neoplasms 2Uterine Cervical Neoplasms 2

Interventions

parsaclisib 2cemiplimab 2Midazolam 2MLN 8237 2Injections 2tanespimycin 1spartalizumab 1repaglinide 1epothilone B 1drospirenone 1cabiralizumab 1Pemetrexed 1Paclitaxel 1Nivolumab 1N-alpha-(2,4,6-triisopropyl-phenylsulfonyl)-3-amidino-(L)-phenyl-alanine-4-ethoxycarbonyl-piperazide hydrochloride 1MLN8054 1Ipilimumab 1Gemcitabine 1Ethinyl Estradiol 1Drug Therapy 1Capecitabine 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Advanced Malignancies × Capecitabine × Clear all
NCT00083525 2008-01-24

Urokinase-Plasminogen Activator (uPA) Inhibitor WX-UK1 in Combination With Capecitabine in Advanced Malignancies

Heidelberg Pharma AG

Phase 1 Completed
33 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡